Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping

Human Brain Mapping

Volumn 36, Issue 11, 2015, Pages 4407-4420

  He, Naying ^a   Ling, Huawei ^a   Ding, Bei ^a   Huang, Juan ^a   Zhang, Yong ^b   Zhang, Zhongping ^b   Liu, Chunlei ^c   Chen, Kemin ^a   Yan, Fuhua ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b GE HEALTHCARE   (China)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Deep grey matter nuclei; Early Parkinson's disease; Iron deposition; Magnetic resonance imaging; Quantitative susceptibility mapping

Indexed keywords

BIOLOGICAL MARKER; IRON;

ADULT; AGED; CAUDATE NUCLEUS; CORPUS STRIATUM; FEMALE; GLOBUS PALLIDUS; HUMAN; MALE; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROCEDURES; PUTAMEN; RED NUCLEUS; SUBSTANTIA NIGRA;

ADULT; AGED; BIOMARKERS; CAUDATE NUCLEUS; CORPUS STRIATUM; FEMALE; GLOBUS PALLIDUS; HUMANS; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE; PUTAMEN; RED NUCLEUS; SUBSTANTIA NIGRA;

EID: 84955726895     PISSN: 10659471     EISSN: 10970193     Source Type: Journal    
DOI: 10.1002/hbm.22928     Document Type: Article

References (80)

1. Andersen JK (2004): Oxidative stress in neurodegeneration: Cause or consequence? Nat Med 10(Suppl):S18-S25.
2. Ayton S, Lei P, Duce JA, Wong BX, Sedjahtera A, Adlard PA, Bush AI, Finkelstein DI (2013): Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Ann Neurol 73:554-559.
3. Barnham KJ, Masters CL, Bush AI (2004): Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discover 3:205-214.
4. Beck AT, Steer R, Brown G, Manual for the BDI-II (1996): San Antonio, TX: The Psychological Corporation. pp 1-38.
5. Ben-Shachar D, Riederer P, Youdim MB (1991): Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem 57:1609-1614.
6. Berg D (2009): Transcranial ultrasound as a risk marker for Parkinson's disease. Mov Disord 24(Suppl 2):S677-S683.
7. Bharathi, Rao KS (2007): Thermodynamics imprinting reveals differential binding of metals to alpha-synuclein: relevance to Parkinson's disease. Biochem Biophys Res Commun 359:115-120.
8. Bilgic B, Pfefferbaum A, Rohlfing T, Sullivan EV, Adalsteinsson E (2012): MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. Neuroimage 59:2625-2635.
9. Bird TD, Shaw CM (1978): Progressive myoclonus and epilepsy with dentatorubral degeneration: A clinicopathological study of the Ramsay Hunt syndrome. J Neurol Neurosurg Psychiatry 41:140-149.
10. Blazejewska AI, Schwarz ST, Pitiot A, Stephenson MC, Lowe J, Bajaj N, Bowtell RW, Auer DP, Gowland PA (2013): Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI. Neurology 81:534-540.
11. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003): Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211.
12. Caslake R, Moore JN, Gordon JC, Harris CE, Counsell C (2008): Changes in diagnosis with follow-up in an incident cohort of patients with parkinsonism. J Neurol Neurosurg Psychiatry 79:1202-1207.
13. Castellani RJ, Siedlak SL, Perry G, Smith MA (2000): Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol 100:111-114.
14. Chen JC, Hardy PA, Kucharczyk W, Clauberg M, Joshi JG, Vourlas A, Dhar M, Henkelman RM (1993): MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. AJNR Am J Neuroradiol 14:275-281.
15. Coupe P, Yger P, Prima S, Hellier P, Kervrann C, Barillot C (2008): An optimized blockwise nonlocal means denoising filter for 3-D magnetic resonance images. IEEE Trans Med Imaging 27:425-441.
16. Damier P, Hirsch EC, Agid Y, Graybiel AM (1999): The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122: 1437-1448.
17. Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, Jonneaux A, Ryckewaert G, Garcon G, Rouaix N, Duhamel A, Jissendi P, Dujardin K, Auger F, Ravasi L, Hopes L, Grolez G, Firdaus W, Sablonnière B, Strubi-Vuillaume I, Zahr N, Destée A, Corvol JC, Pöltl D, Leist M, Rose C, Defebvre L, Marchetti P, Cabantchik ZI, Bordet R (2014): Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal 21:195-210.
18. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD (1991): Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114: 1953-1975.
19. Monte D, Tanner DA, Andersen CM, Quik J, Langston MJW (2003): Environmental and genetic determinants of PD. Neurotoxicology 24:293-294.
20. Double KL, Gerlach M, Youdim MB, Riederer P (2000): Impaired iron homeostasis in Parkinson's disease. J Neural Transm 60:37-58.
21. Drayer B, Burger P, Darwin R, Riederer S, Herfkens R, Johnson GA (1986): MRI of brain iron. AJR Am J Roentgenol 147:103-110.
22. Du G, Lewis MM, Styner M, Shaffer ML, Sen S, Yang QX, Huang X (2011): Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov Disord 26:1627-1632.
23. Dusek P, Jankovic J, Le W (2012): Iron dysregulation in movement disorders. Neurobiol Dis 46:1-18.
24. Eapen M, Zald DH, Gatenby JC, Ding Z, Gore JC (2011): Using high-resolution MR imaging at 7T to evaluate the anatomy of the midbrain dopaminergic system. AJNR Am J Neuroradiol 32:688-694.
25. Fahn S, Elton RL, Committee UD (1987): Unified Parkinson's disease rating scale. Recent Dev Parkinson's Dis 2:153-163.
26. Fasano M, Bergamasco B, Lopiano L (2006): Modifications of the iron-neuromelanin system in Parkinson's disease. J Neurochem 96:909-916.
27. Fernandez-Seara MA, Wehrli FW (2000): Postprocessing technique to correct for background gradients in image-based R*(2) measurements. Magn Reson Med 44:358-366.
28. Folstein MF, Folstein SE, McHugh PR (1975): "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198.
29. Gerlach M, Double KL, Ben-Shachar D, Zecca L, Youdim MB, Riederer P (2003): Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Neurotox Res 5:35-44.
30. Gerlach M, Double KL, Youdim MB, Riederer P (2006): Potential sources of increased iron in the substantia nigra of Parkinsonian patients. J Neural Transm 70:133-142.
31. Gille G, Reichmann H (2011): Iron-dependent functions of mitochondria-Relation to neurodegeneration. J Neural Transm 118:349-359.
32. Good PF, Olanow CW, Perl DP (1992): Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: A LAMMA study. Brain Res 593:343-346.
33. Graham JM, Paley MN, Grunewald RA, Hoggard N, Griffiths PD (2000): Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 123:2423-2431.
34. Griffiths PD, Crossman AR (1993): Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia 4:61-65.
35. Griffiths PD, Dobson BR, Jones GR, Clarke DT (1999): Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 122: 667-673.
36. Habas C, Cabanis EA (2007): Cortical projection to the human red nucleus: Complementary results with probabilistic tractography at 3 T. Neuroradiology 49:777-784.
37. Hallgren B, Sourander P (1958): The effect of age on the non-haemin iron in the human brain. J Neurochem 3:41-51.
38. He Q, Song N, Xu H, Wang R, Xie J, Jiang H (2011): Alpha-synuclein aggregation is involved in the toxicity induced by ferric iron to SK-N-SH neuroblastoma cells. J Neural Transm 118:397-406.
39. Hikishima K, Ando K, Komaki Y, Kawai K, Yano R, Inoue T, Itoh T, Yamada M, Momoshima S, Okano HJ, Okano H (2015): Voxel-based morphometry of the marmoset brain: in vivo detection of volume loss in the substantia nigra of the MPTP-treated Parkinson's disease model. Neuroscience 300:585-592.
40. Hoehn MM, Yahr MD (1967): Parkinsonism: onset, progression and mortality. Neurology 17:427-442.
41. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992): Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184.
42. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982): A new clinical scale for the staging of dementia. Br J Psychiatry 140:566-572.
43. Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MB (1990): Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect 2:327-340.
44. Jin L, Wang J, Jin H, Fei G, Zhang Y, Chen W, Zhao L, Zhao N, Sun X, Zeng M, Zhong C (2012): Nigral iron deposition occurs across motor phenotypes of Parkinson's disease. Eur J Neurol 19:969-976.
45. Jin L, Wang J, Zhao L, Jin H, Fei G, Zhang Y, Zeng M, Zhong C (2011): Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain 134:50-58.
46. Kosta P, Argyropoulou MI, Markoula S, Konitsiotis S (2006): MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease. J Neurol 253:26-32.
47. Kwon DH, Kim JM, Oh SH, Jeong HJ, Park SY, Oh ES, Chi JG, Kim YB, Jeon BS, Cho ZH (2012): Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol 71:267-277.
48. Langkammer C, Schweser F, Krebs N, Deistung A, Goessler W, Scheurer E, Sommer K, Reishofer G, Yen K, Fazekas F, Ropele S, Reichenbach JR (2012): Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. Neuroimage 62:1593-1599.
49. Lapresle J, Hamida MB (1970): The dentato-olivary pathway. Somatotopic relationship between the dentate nucleus and the contralateral inferior olive. Arch Neurol 22:135-143.
50. Lee J, Shmueli K, Fukunaga M, van Gelderen P, Merkle H, Silva AC, Duyn JH (2010): Sensitivity of MRI resonance frequency to the orientation of brain tissue microstructure. Proc Natl Acad Sci USA 107:5130-5135.
51. Lewis MM, Du G, Kidachi M, Patel N, Shaffer ML, Mailman RB, Huang X (2012): Higher iron in the red nucleus marks Parkinson's dyskinesia. Ann Neurol 72:S97-S98.
52. Lewis MM, Du G, Kidacki M, Patel N, Shaffer ML, Mailman RB, Huang X (2013): Higher iron in the red nucleus marks Parkinson's dyskinesia. Neurobiol Aging 34:1497-1503.
53. Li W, Langkammer C, Chou YH, Petrovic K, Schmidt R, Song AW, Madden DJ, Ropele S, Liu C. (2014a): Association between increased magnetic susceptibility of deep gray matter nuclei and decreased motor function in healthy adults. Neuroimage 105:45-52.
54. Li W, Wang N, Yu F, Han H, Cao W, Romero R, Tantiwongkosi B, Duong TQ, Liu C. (2015): A method for estimating and removing streaking artifacts in quantitative susceptibility mapping. Neuroimage 108:111-122.
55. Li W, Wu B, Avram AV, Liu C (2012): Magnetic susceptibility anisotropy of human brain in vivo and its molecular underpinnings. Neuroimage 59:2088-2097.
56. Li W, Wu B, Batrachenko A, Bancroft-Wu V, Morey RA, Shashi V, Langkammer C, De Bellis MD, Ropele S, Song AW, Liu C (2014b): Differential developmental trajectories of magnetic susceptibility in human brain gray and white matter over the lifespan. Hum Brain Mapp 35:2698-2713.
57. Li W, Wu B, Liu C (2011): Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition. Neuroimage 55:1645-1656.
58. Li WJ, Jiang H, Song N, Xie JX (2010): Dose- and time-dependent alpha-synuclein aggregation induced by ferric iron in SK-N-SH cells. Neurosci Bull 26:205-210.
59. Liu C (2010): Susceptibility tensor imaging. Magn Reson Med 63:1471-1477.
60. Liu T, Eskreis-Winkler S, Schweitzer AD, Chen W, Kaplitt MG, Tsiouris AJ, Wang Y (2013): Improved subthalamic nucleus depiction with quantitative susceptibility mapping. Radiology 269:216-223.
61. Liu T, Spincemaille P, de Rochefort L, Kressler B, Wang Y (2009): Calculation of susceptibility through multiple orientation sampling (COSMOS): a method for conditioning the inverse problem from measured magnetic field map to susceptibility source image in MRI. Magn Reson Med 61:196-204.
62. Logroscino G, Marder K, Graziano J, Freyer G, Slavkovich V, Lojacono N, Cote L, Mayeux R. (1998): Dietary iron, animal fats, and risk of Parkinson's disease. Mov Disord 13(Suppl 1):13-16.
63. Lotfipour AK, Wharton S, Schwarz ST, Gontu V, Schafer A, Peters AM, Bowtell RW, Auer DP, Gowland PA, Bajaj NP (2012): High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease. J Magn Reson Imaging 35:48-55.
64. Martin WR, Wieler M, Gee M (2008a): Midbrain iron content in early Parkinson disease: A potential biomarker of disease status. Neurology 70:1411-1417.
65. Martin WRW, Wieler M, Gee M (2008b): Midbrain iron content in early Parkinson disease - A potential biomarker of disease status. Neurology 70:1411-1417.
66. Ostrerova-Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, Wolozin B (2000): The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 20:6048-6054.
67. Peran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, Peppe A, Celsis P, Rascol O, Demonet J-F, Stefani A, Pierantozzi M, Pontieri FE, Caltagirone C, Spalletta G, Sabatini U (2010): Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 133:3423-3433.
68. Rhodes SL, Buchanan DD, Ahmed I, Taylor KD, Loriot M-A, Sinsheimer JS, Bronstein JM, Elbaz A, Mellick GD, Rotter JI, Ritz B (2014): Pooled analysis of iron-related genes in Parkinson's disease: Association with transferrin. Neurobiol Dis 62:172-178.
69. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MB (1989): Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52:515-520.
70. Ryvlin P, Broussolle E, Piollet H, Viallet F, Khalfallah Y, Chazot G (1995): Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease. Arch Neurol 52:583-588.
71. Schafer A, Wharton S, Gowland P, Bowtell R (2009): Using magnetic field simulation to study susceptibility-related phase contrast in gradient echo MRI. Neuroimage 48:126-137.
72. Schwarz ST, Afzal M, Morgan PS, Bajaj N, Gowland PA, Auer DP (2014): The 'swallow tail' appearance of the healthy nigrosome - A new accurate test of Parkinson's disease: A case-control and retrospective cross-sectional MRI study at 3T. PLos One 9:e93814.
73. Schweser F, Deistung A, Lehr BW, Reichenbach JR (2011): Quantitative imaging of intrinsic magnetic tissue properties using MRI signal phase: An approach to in vivo brain iron metabolism? Neuroimage 54:2789-2807.
74. Shmueli K, de Zwart JA, van Gelderen P, Li TQ, Dodd SJ, Duyn JH (2009): Magnetic susceptibility mapping of brain tissue in vivo using MRI phase data. Magn Reson Med 62:1510-1522.
75. Sukstanskii AL, Yablonskiy DA (2014): On the role of neuronal magnetic susceptibility and structure symmetry on gradient echo MR signal formation. Magn Reson Med 71:345-353.
76. Torsdottir G, Kristinsson J, Sveinbjornsdottir S, Snaedal J, Johannesson T (1999): Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. Pharmacol Toxicol 85:239-243.
77. Wallis LI, Paley MNJ, Graham JM, Gruenewald RA, Wignall EL, Joy HM, Griffiths PD (2008): MRI assessment of basal ganglia iron deposition in Parkinson's disease. J Magn Reson Imaging 28:1061-1067.
78. Wu B, Li W, Guidon A, Liu C (2012): Whole brain susceptibility mapping using compressed sensing. Magn Reson Med 67:137-147.
79. Zecca L, Casella L, Albertini A, Bellei C, Zucca FA, Engelen M, Zadlo A, Szewczyk G, Zareba M, Sarna T (2008): Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J Neurochem 106:1866-1875.
80. Zukor H, Song W, Liberman A, Mui J, Vali H, Fillebeen C, Pantopoulos K, Wu TD, Guerquin-Kern JL, Schipper HM (2009): HO-1-mediated macroautophagy: a mechanism for unregulated iron deposition in aging and degenerating neural tissues. J Neurochem 109:776-791.